Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Liabilities: 2014-2025

Historic Total Liabilities for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $26.4 million.

  • Viking Therapeutics' Total Liabilities fell 0.21% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year decrease of 0.21%. This contributed to the annual value of $28.0 million for FY2024, which is 39.72% up from last year.
  • Per Viking Therapeutics' latest filing, its Total Liabilities stood at $26.4 million for Q3 2025, which was down 18.54% from $32.4 million recorded in Q2 2025.
  • Viking Therapeutics' Total Liabilities' 5-year high stood at $33.6 million during Q1 2024, with a 5-year trough of $8.8 million in Q4 2021.
  • Moreover, its 3-year median value for Total Liabilities was $25.9 million (2024), whereas its average is $23.5 million.
  • As far as peak fluctuations go, Viking Therapeutics' Total Liabilities surged by 164.38% in 2022, and later crashed by 40.30% in 2025.
  • Over the past 5 years, Viking Therapeutics' Total Liabilities (Quarterly) stood at $8.8 million in 2021, then soared by 164.38% to $23.2 million in 2022, then fell by 13.51% to $20.1 million in 2023, then spiked by 39.72% to $28.0 million in 2024, then fell by 0.21% to $26.4 million in 2025.
  • Its Total Liabilities was $26.4 million in Q3 2025, compared to $32.4 million in Q2 2025 and $20.1 million in Q1 2025.